gptkbp:instance_of
|
gptkb:immunotherapy
|
gptkbp:approves
|
gptkb:1995
gptkb:FDA
|
gptkbp:atccode
|
J05 AF05
|
gptkbp:brand
|
gptkb:3_TC
gptkb:Epivir
|
gptkbp:can_be_combined_with
|
gptkb:abacavir
gptkb:tenofovir
gptkb:zidovudine
|
gptkbp:casnumber
|
134678-17-4
|
gptkbp:category
|
gptkb:C
|
gptkbp:chemical_formula
|
C8 H11 N3 O3 S
|
gptkbp:class
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
gptkbp:clinical_use
|
HIV-1 infection
HIV-1 prophylaxis
HIV-1 treatment
|
gptkbp:contraindication
|
hypersensitivity to lamivudine
|
gptkbp:dosage_form
|
oral solution
film-coated tablet
|
gptkbp:drug_interactions
|
gptkb:trimethoprim/sulfamethoxazole
probenecid
dapsone
|
gptkbp:excretion
|
renal
|
gptkbp:form
|
gptkb:Software_Solutions
gptkb:tablet
|
https://www.w3.org/2000/01/rdf-schema#label
|
Epivir
|
gptkbp:indication
|
gptkb:chronic_hepatitis_B
|
gptkbp:ingredients
|
gptkb:lamivudine
|
gptkbp:invention
|
gptkb:2016
|
gptkbp:lifespan
|
5 to 7 hours
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
gptkbp:marketed_as
|
gptkb:3_TC
|
gptkbp:metabolism
|
hepatic
|
gptkbp:previous_name
|
yes
|
gptkbp:route_of_administration
|
oral
|
gptkbp:safety_measures
|
lactic acidosis
hepatomegaly
immune reconstitution syndrome
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
|
gptkbp:used_for
|
treatment of HIV
|
gptkbp:bfsParent
|
gptkb:lamivudine
|
gptkbp:bfsLayer
|
6
|